Journal
CARDIOLOGY CLINICS
Volume 36, Issue 2, Pages 241-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccl.2017.12.006
Keywords
PCSK9; Monoclonal antibodies; Evolocumab; Alirocumab; LDL-C; Hypercholesterolemia; Cardiovascular disease; Proprotein convertase subtilisin kexin 9
Categories
Funding
- Aegerion
- Amgen
- AstraZeneca
- Eli Lilly
- Genzyme
- Mediolanum
- Merck
- MSD
- Pfizer
- Recordati
- Rottapharm
- Sanofi-Regeneron
- Sigma-Tau
Ask authors/readers for more resources
High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy. However, many patients cannot achieve the recommended LDL-C levels with current therapies. The discovery of the role of proprotein convertase subtilisin kexin 9 (PCSK9) in the regulation of plasma LDL-C levels suggested it as a potential pharmacologic target and led to the development of PCSK9 inhibitors for the management of LDL-C levels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available